

November 29, 2017

To whom it may concern:

Company Name Corporate Representative	TOHO HOLDINGS CO., LTD. Norio Hamada, Chairman of the Board and Representative Director (First Section of Tokyo Stock Exchange Securities Code:8129)
Contact:	Makoto Kawamura, Corporate Officer, General Manager, Public and Investor Relations Department (TEL: 81-3-6838-2803)

Notice Regarding Approval of Partial Amendments to Indications, Dosage and Administration of Famciclovir Tablets 250mg “KYOSOMIRAI” for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director: Norio Hamada; hereinafter, “TOHO HOLDINGS”) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Atsushi Udoh; hereinafter, “KYOSOMIRAI PHARMA”), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, received an approval of partial amendments to indications, dosage and administration of Famciclovir Tablets 250mg “KYOSOMIRAI” on November 29, 2017 as below.

Outline of Famciclovir Tablets 250mg “KYOSOMIRAI”

Class	Product Name	Original Brand Name
Anti-herpesvirus agents	Famciclovir Tablets 250mg ”KYOSOMIRAI”	Famvir Tablets 250mg

Outline of Amendments to Indications, Dosage and Administration of Famciclovir Tablets 250mg “KYOSOMIRAI”

Indications and Usage	<u>Herpes simplex</u> Herpes zoster
Dosage and Administration	<u>Herpes simplex :</u> <u>Normally, for adults: 250 mg orally, three times daily</u> <u>Herpes zoster :</u> <u>Normally, for adults:500 mg orally, three times daily</u>

(Underlined parts are revised parts.)

KYOSOMIRAI PHARMA CO., LTD.

KYOSOMIRAI PHARMA was established on November 1, 2016 as the wholly-owned subsidiary of TOHO HOLDINGS which engages in business such as pharmaceutical wholesaling, management of pharmacies, and development and provision of customer support systems under the corporate slogan, “Total commitment to good health”. KYOSOMIRAI PHARMA involves in development, manufacture and sales business of prescription pharmaceuticals centered on generic drugs as well as contracted manufacture of them. Establishing a business scheme of integrated manufacture and sales which accurately responds to customers’ demands, KYOSOMIRAI PHARMA aims to stably and effectively provide high quality and high value added prescription pharmaceuticals mainly for generic drugs.

【Outline of KYOSOMIRAI PHARMA】

Company Name	KYOSOMIRAI PHARMA CO., LTD.
Head Office	1-4-4 Hiromachi, Shinagawa-ku, Tokyo 140-0005, Japan
Marunouchi Office	Gran Tokyo South Tower 12F, 1-9-2 Marunouchi, Chiyoda-ku, Tokyo100-6612, Japan
Executives	Representative director and senior advisor: Norio Hamada Representative director and chairman: Ryuzo Takada Representative director and president: Atsushi Udoh
Business Contents	Manufacture and sales of prescription pharmaceuticals, Contracted manufacture of injectable pharmaceuticals